C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Invests $71,000 in Dynavax Technologies Co. (NASDAQ:DVAX)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 5,540 shares of the biopharmaceutical company’s stock, valued at approximately $71,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Entropy Technologies LP lifted its holdings in shares of Dynavax Technologies by 17.2% during the 4th quarter. Entropy Technologies LP now owns 48,621 shares of the biopharmaceutical company’s stock worth $621,000 after acquiring an additional 7,121 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Dynavax Technologies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 27,873 shares of the biopharmaceutical company’s stock worth $356,000 after acquiring an additional 2,669 shares during the period. KBC Group NV lifted its holdings in shares of Dynavax Technologies by 68.7% during the 4th quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 2,857 shares during the period. Exchange Traded Concepts LLC lifted its holdings in shares of Dynavax Technologies by 4.3% during the 4th quarter. Exchange Traded Concepts LLC now owns 162,726 shares of the biopharmaceutical company’s stock worth $2,078,000 after acquiring an additional 6,712 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of Dynavax Technologies during the 4th quarter worth approximately $990,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

DVAX stock opened at $12.82 on Friday. The company has a 50 day simple moving average of $12.80 and a 200 day simple moving average of $11.93. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of 98.62 and a beta of 1.32. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $13.89. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Wall Street Analysts Forecast Growth

DVAX has been the subject of a number of research analyst reports. The Goldman Sachs Group cut shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price objective for the stock from $15.00 to $12.00 in a research report on Tuesday. StockNews.com cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, HC Wainwright upped their price objective on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.